Dosage Forms

Articles

Vectura has signed an agreement with Incannex Healthcare for the pre-clinical development of IHL-216A, an inhaled drug product for the treatment of traumatic brain injury.

Vectura Signs Agreement with Incannex to Advance TBI Treatment

Vectura and Inspira Pharmaceuticals have joined forces to develop a potential inhaled therapy for COVID-19.

Vectura, Inspira Pharmaceuticals Team Up to Develop Potential Inhaled COVID-19 Treatment

The expansion plans to increase Vectura’s DPI dosage form development, specifically its unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs.

Vectura Announces Dry Powder Inhaler Capabilities Expansion at UK Facility 

A development agreement will study inhaled formulations of cannabinoid-based drug product for central nervous system diseases.

Kindeva and BOL Pharma to Develop Inhaled Cannabinoid Products

Vectura will support the product from Phase I through to commercial launch. 



Vectura and Monash University to Develop Inhaled Oxytocin for the Prevention of Postpartum Hemorrhage

Creating an inhaled formulation is one way in which improved efficacy or added value can be achieved in projects to repurpose or reposition existing drugs.

Key Considerations When Repositioning a Known Drug for Inhalation Therapy

The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.

Bilim, H&T Presspart, and Hovione Partner to Bring Asthma Product to the Turkish Market

Inhalation drug delivery company Vectura announces new organizational structure to drive innovation, customer focus, and growth.

Vectura Appoints Sharon Johnson Executive VP

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

A simple, one-part DPI aims to make inhalation drug treatment more accessible and affordable.

Hovione Technology Develops Blister-Based Inhaler

Consider both the device characteristics and the powder properties when developing a DPI combination product.

Inhalation Drugs